USANA Health Sciences, Inc. updated earnings guidance for the year 2023. Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.57 USD | +0.13% |
|
+1.36% | -14.98% |
07/05 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
01/05 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.98% | 868M | |
+13.80% | 8.17B | |
+0.47% | 7.31B | |
-8.08% | 5.43B | |
-6.72% | 3.69B | |
-19.73% | 3.2B | |
-12.00% | 1.21B | |
-26.74% | 1.12B | |
+0.89% | 868M | |
-12.89% | 836M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023